Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-ranging study of clazakizumab with or without methotrexate in moderate to severe rheumatoid arthritis
2010-023956-99Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clazakizumab in rheumatoid arthritis (RA) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: ACR20 response rate (primary). Started May 2011; status: completed.
02
Drugs
clazakizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-023956-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023956-99.